Editor-The ATACAS trial, which enrolled 2100 patients to evaluate the effects of preoperative aspirin in patients undergoing cardiac surgery, has now been published. 1 Given that large trials provide more robust estimates of effect and with greater internal and external validity, 2 3 and increase the validity and reliability of meta-analyses, 4 we therefore updated our recent meta-analysis published in the BJA last year. 5 We repeated our systematic review using our previous methodology, which now includes 13 randomized trials and 4499 patients. For postoperative myocardial infarction (MI) the sample size has increased from 1437 to 3535 patients, resulting in an increase in MI events from 56 to 366 -see Fig. 1 . This updated metaanalysis shows that continuing aspirin up until the day of surgery, reduces the risk of postoperative MI with no evidence of heterogeneity (I 2 =0), odds ratio (OR) 0.79 (95% CI: 0.64-0.99),
We repeated our systematic review using our previous methodology, which now includes 13 randomized trials and 4499 patients.
For postoperative myocardial infarction (MI) the sample size has increased from 1437 to 3535 patients, resulting in an increase in MI events from 56 to 366 -see Fig. 1 . This updated metaanalysis shows that continuing aspirin up until the day of surgery, reduces the risk of postoperative MI with no evidence of heterogeneity (I 2 =0), odds ratio (OR) 0.79 (95% CI: 0.64-0.99),
P=0.04.
We also provide updates of the estimates of effect for recent aspirin exposure for: (i) surgical blood loss, weighted mean difference 151 mL (95% CI: 37-265 mL), P=0.01; (ii) red cell transfusion, weighted mean difference 119 mL (95% CI: 47-192 mL), P=0.001; (iii) surgical re-exploration, OR 1.40 (95% CI: 0.97-2.03), P=0.07; and (v) all-cause mortality, OR 1.39 (95% CI: 0.73-2.63), P=0.31.
Given the minimal adverse effects of aspirin on bleeding complications, and a likely reduction in MI, this updated metaanalysis supports a recommendation that aspirin be continued up until the day of coronary artery surgery. We believe we have gone much further than many departments in the last few yr with respect to the implementation of VL. For several yr we had VL (Storz C-MAC standard and D-blades, Slough, Berkshire, UK) available for use in each of three theatre suites, for use as a rescue device. In 2012 we undertook a trial of conversion to routine use of VL for all intubations of adults: since that time VL has been available in all operating theatres, and has been used as the first choice laryngoscope for approximately 80% of intubations. Dr Dawson and colleagues 2 raised concern regarding a reduction in rates of fibreoptic intubation (FOI), since the introduction of VL. In contrast to their experience, and despite widespread adoption of VL, we have seen no reduction in FOI: in 2012, the rate of FOI was one in every 157 intubations (one in every 497 general anaesthetics), which increased to one in 109 intubations in 2013, and one in 127 intubations in 2014. We have therefore not seen a reduction in opportunities to train in or perform FOI.
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